A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM)

Waldenstrom Macroglobulinemia Clinical Trial

Official title:

A Single Arm, Multicenter, Phase 4 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) in Chinese Subjects With Relapse or Refractory Waldenström's Macroglobulinemia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04042376
• Other study ID #: CR108654
• Secondary ID: 54179060WAL4001
• Status: Completed
• Phase: Phase 4
• Start date: December 18, 2019
• Est. completion date: March 19, 2024

Study information

• Verified date: April 2024
• Source: Janssen Research & Development, LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy of ibrutinib based on overall response rate (ORR) (partial response [PR] or better) by investigator assessment per the modified Consensus Response Criteria from the Sixth International Workshop on Waldenstrom's Macroglobulinemia (IWWM) (NCCN 2019), in Chinese participants with relapsed or refractory waldenstrom's macroglobulinemia.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 17
• Est. completion date: March 19, 2024
• Est. primary completion date: March 19, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Men and women greater than or equal to (>=) 18 years of age
• Eastern Cooperative Oncology Group (ECOG) less than or equal to (<=) 2
• Previously received at least one prior therapy for WM and have had either documented disease progression or had no response to the most recent treatment regimen
• Centrally confirmed clinicopathological diagnosis of WM
• Measurable disease defined as serum monoclonal immunoglobulin M (IgM) >0.5 gram per deciliter (g/dL)
• Symptomatic disease, requiring treatment
• Hematology and biochemical values within protocol-defined limits
• Female participants of childbearing potential must have a negative serum pregnancy test at screening and agree to use highly effective methods of contraception while taking study drug. Female participants of childbearing potential should avoid becoming pregnant while taking ibrutinib and for up to 1 month after the last dose of study drug. Male participants must use an effective barrier method of contraception during the study and for 3 months following the last dose of ibrutinib if sexually active with a female of childbearing potential

Exclusion Criteria:

• Involvement of the central nervous system by WM
• Evidence of disease transformation
• Prior exposure to BTK inhibitors
• Known hypersensitivity reaction to ibrutinib or to the excipients in its formulation
• Received any WM-related therapy <=30 days prior to first administration of study treatment
• Received a prior allogeneic hematopoietic stem cell transplant
• Plasmapheresis <35 days prior to the initiation of study drug, except when at least one serum IgM central assessment was performed during the screening period and was >35 days from the most recent plasmapheresis procedure
• History of other malignancies, except: (a) malignancy treated with curative intent and with no known active disease present for >=2 years before the first dose of study drug and felt to be at low risk for recurrence by treating physician; (b) adequately treated nonmelanoma skin cancer or lentigo maligna without evidence of disease; (c) adequately treated carcinoma in situ without evidence of disease
• Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug
• Infection requiring systemic treatment that was completed <=14 days before the first dose of study drug
• Bleeding disorders or hemophilia
• Stroke or intracranial hemorrhage within 6 months prior to enrollment
• Infection with human immunodeficiency virus (HIV) or active infection with hepatitis B or hepatitis C
• Major surgery within 4 weeks of first dose of study drug
• Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the participant's safety or put the study outcomes at undue risk
• Currently active, clinically significant hepatic impairment Child-Pugh Class B or C according to the Child Pugh classification
• Currently active, clinically significant cardiovascular disease
• Requires or receiving anticoagulation with warfarin or other Vitamin K antagonists
• Unable to swallow capsules or malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction
• Requires treatment with a strong cytochrome P450 (CYP) 3A inhibitor
• Lactating or pregnant
• Unable to understand the purpose and risks of the study and to provide a signed and dated informed consent form (ICF) and authorization to use protected health information (in accordance with national and local participant privacy regulations)

Related Conditions & MeSH terms

• Waldenstrom Macroglobulinemia

Intervention

Drug:
• Ibrutinib
Ibrutinib will be administered orally, once daily, at a dose of 420 mg (140 mg*3 capsules taken together at one time).

Locations

Country	Name	City	State
China	The First Hospital of Jilin University	Changchun
China	First affiliated Hospital of Zhejiang University	Hangzhou
China	Institute of Hematology and Blood Diseases Hospital	Tianjin
China	Wuhan Union Hospital	Wuhan
China	The Second Affiliated Hospital of Xi'an Jiaotong University	Xi'an
China	Henan Cancer Hospital	Zhengzhou

Sponsors (1)

Lead Sponsor	Collaborator
Janssen Research & Development, LLC

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Response Rate (ORR)	ORR is defined as the percentage of participants who achieve partial response (PR) or better per the modified Consensus Response Criteria from the 6th International Workshop on Waldenstrom Macroglobulinemia (IWWM) (NCCN 2019) as assessed by the investigator.	Up to 4 years
Secondary	Percentage of Participants Achieving Clinical Response Rate (CRR)	CRR is defined as the percentage of participants who achieve minor response (MR) or better according to the modified 4th IWWM (NCCN 2019) criteria as assessed by the investigator.	Up to 4 years
Secondary	Percentage of Participants Achieving Very Good Partial Response (VGPR) or Better Response	VGPR or better rate is defined as the percentage of participants who achieve VGPR or better according to the modified 4th IWWM (NCCN 2019) criteria as assessed by the investigator.	Up to 4 years
Secondary	Duration of Response (DOR)	DOR is defined as duration from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease or death for responders (PR or better) as assessed by the investigator.	Up to 4 years
Secondary	Time to Response (TTR)	TTR is defined as the time from the date of first dose to the date of initial documentation of a response (PR or better).	Up to 4 years
Secondary	Progression Free Survival (PFS)	PFS is defined as duration from the date of first dose to the date of disease progression or death, whichever is first reported, assessed according to the modified 6th IWWM (NCCN 2019) criteria.	Up to 4 years
Secondary	Overall Survival (OS)	OS is defined as the time from the date of first dose to the date of the participant's death from any cause.	Up to 4 years
Secondary	Trough Plasma Concentration (Ctrough) of Ibrutinib	Ctrough is defined as the observed plasma concentration before dosing or at the end of the dosing interval.	Day 1 of Weeks 1, 5 and 9
Secondary	Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability	An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.	Up to 4 years